米诺环素治疗散发性与遗传性脑淀粉样血管病(BATMAN):安慰剂对照随机双盲试验研究方案
BATMAN研究为安慰剂对照随机双盲试验,纳入60例脑淀粉样血管病患者(30例遗传性荷兰型CAA,30例散发性CAA),随机接受米诺环素或安慰剂治疗3个月,主要结局为脑脊液中神经炎症标志物(IL-6、MCP-1、IBA-1)和明胶酶通路标志物(MMP2/9、VEGF),并评估7-T MRI出血标志物进展及血清生物标志物。
要点
- BATMAN试验纳入60例CAA患者(30例遗传性荷兰型,30例散发性),随机接受米诺环素或安慰剂治疗3个月。
- 主要结局为脑脊液神经炎症标志物(IL-6、MCP-1、IBA-1)和明胶酶通路标志物(MMP2/9、VEGF)。
- 次要结局包括7-T MRI出血标志物进展及血清生物标志物。
核心结论
- 该概念验证研究的结果将用于评估米诺环素对CAA的靶点结合潜力。
研究设计与样本
- BATMAN为安慰剂对照随机双盲试验,纳入60例CAA患者,其中30例遗传性荷兰型CAA和30例散发性CAA。
- 受试者随机接受安慰剂或米诺环素(散发性CAA米诺环素15例/遗传性荷兰型CAA米诺环素15例,散发性CAA安慰剂15例/遗传性荷兰型CAA安慰剂15例)。
- 在基线(t=0)和3个月(t=3个月)时收集脑脊液和血液样本、进行7-T MRI并收集人口学特征。
主要发现
- 主要结局指标为脑脊液中神经炎症标志物(IL-6、MCP-1和IBA-1)和明胶酶通路标志物(MMP2/9和VEGF)。
- 次要方面将观察治疗前后7-T MRI上出血标志物的进展并研究血清生物标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cerebral amyloid angiopathy (CAA) is a disease caused by the accumulation of the amyloid-beta protein and is a major cause of intracerebral hemorrhage (ICH) and vascular dementia in the elderly. The presence of the amyloid-beta protein in the vessel wall may induce a chronic state of cerebral inflammation by activating astrocytes, microglia, and pro-inflammatory substances. Minocycline, an antibiotic of the tetracycline family, is known to modulate inflammation, gelatinase activity, and angiogenesis. These processes are suggested to be key mechanisms in CAA pathology. Our aim is to show the target engagement of minocycline and investigate in a double-blind placebo-controlled randomized clinical trial whether treatment with minocycline for 3 months can decrease markers of neuroinflammation and of the gelatinase pathway in cerebrospinal fluid (CSF) in CAA patients. METHODS: The BATMAN study population consists of 60 persons: 30 persons with hereditary Dutch type CAA (D-CAA) and 30 persons with sporadic CAA. They will be randomized for either placebo or minocycline (15 sporadic CAA/15 D-CAA minocycline, 15 sporadic CAA/15 D-CAA placebo). At t = 0 and t = 3 months, we will collect CSF and blood samples, perform a 7-T MRI, and collect demographic characteristics. DISCUSSION: The results of this proof-of-principle study will be used to assess the potential of target engagement of minocycline for CAA. Therefore, our primary outcome measures are markers of neuroinflammation (IL-6, MCP-1, and IBA-1) and of the gelatinase pathway (MMP2/9 and VEGF) in CSF. Secondly, we will look at the progression of hemorrhagic markers on 7-T MRI before and after treatment and investigate serum biomarkers. TRIAL REGISTRATION: ClinicalTrials.gov NCT05680389. Registered on January 11, 2023.
引用
- Voigt S, Koemans EA, Rasing I, et al. Minocycline for sporadic and hereditary cerebral amyloid angiopathy (BATMAN): study protocol for a placebo-controlled randomized double-blind trial. Trials. 2023. PMID: 37277877. doi:10.1186/s13063-023-07371-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。